Advanced Search
Contact | Corporate | Help

Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa

Sponsors:
  • New York University School of Medicine
  • Genentech
Phases:
  • Phase I
IndicationsAcronym:
  • Hidradenitis Suppurativa
Age Groups:
  • Adult
Gender:
Female
Names:
  • Drug: efalizumab
Enrollment:
5

Additional information about NCT00134134.


SourceSolution © 2008-2012